{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:57:51Z","timestamp":1787003871732,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Shiga toxin 2 (Stx2) is a major virulence factor in infections with Stx-producing\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    (STEC), which can cause serious clinical complications in humans, such as hemolytic uremic syndrome (HUS). Recently, we screened and identified two peptide-based Stx2 neutralizers, TF-1 and WA-8, which specifically and directly bind to Stx2. Computer simulations suggested that the majority of TF-1 or WA-8 binds tightly at the receptor-binding site 3 of Stx2. The two peptides also effectively inhibited the cytotoxic activity of Stx2 by blocking the binding of Stx2 to target cells. TF-1 exhibits remarkable therapeutic potency in both mice and rat toxicity models. In mice toxicity models, TF-1 provided full protection when mice were injected with 5 LD\n                    <jats:sub>50<\/jats:sub>\n                    of Stx2. In rat toxicity models, TF-1 reduced fatal tissue damage and completely protected rats from the lethal challenges of Stx2. In these rats, TF-1 significantly decreased the concentration of Stx2 in blood and diminished tissue distribution levels of Stx2. Furthermore, TF-1 effectively protected rats from the pathological effects caused by Stx2, especially in the kidney, thymus, adrenal gland, and lung. Taken together, these results indicate that TF-1 is a promising therapeutic agent against the pathogenicity of Stx2.\n                  <\/jats:p>","DOI":"10.1038\/srep21837","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T05:15:43Z","timestamp":1456204543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo"],"prefix":"10.1038","volume":"6","author":[{"given":"Tao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuenan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzhi","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"BFsrep21837_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.toxicon.2012.07.016","volume":"60","author":"J Bergan","year":"2012","unstructured":"Bergan, J., Lingelem, A. B. D., Simm, R., Skotland, T. & Sandvig, K. Shiga toxins. Toxicon 60, 1085\u20131107 (2012).","journal-title":"Toxicon"},{"key":"BFsrep21837_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/emmm.201201662","volume":"4","author":"H Karch","year":"2012","unstructured":"Karch, H. et al. The enemy within us: lessons from the 2011 European Escherichia coli O104: H4 outbreak. EMBO Mol. Med. 4, 841\u2013848 (2012).","journal-title":"EMBO Mol. Med."},{"key":"BFsrep21837_CR3","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","volume":"365","author":"C Frank","year":"2011","unstructured":"Frank, C. et al. Epidemic profile of Shiga-toxin\u2013producing Escherichia coli O104: H4 outbreak in Germany. N. Engl. J. Med. 365, 1771\u20131780 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep21837_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nrneph.2012.196","volume":"8","author":"H Trachtman","year":"2012","unstructured":"Trachtman, H., Austin, C., Lewinski, M. & Stahl, R. A. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat. Rev. Nephrol. 8, 658\u2013669 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFsrep21837_CR5","first-page":"195","volume":"6","author":"LS Keir","year":"2012","unstructured":"Keir, L. S., Marks, S. D. & Kim, J. J. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des. Devel. Ther. 6, 195 (2012).","journal-title":"Drug Des. Devel. Ther."},{"key":"BFsrep21837_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrmicro2279","volume":"8","author":"L Johannes","year":"2010","unstructured":"Johannes, L. & R\u00f6mer, W. Shiga toxins\u2014from cell biology to biomedical applications. Nat. Rev. Microbiol. 8, 105\u2013116 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFsrep21837_CR7","doi-asserted-by":"publisher","first-page":"27511","DOI":"10.1074\/jbc.M401939200","volume":"279","author":"ME Fraser","year":"2004","unstructured":"Fraser, M. E. et al. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 279, 27511\u201327517, 10.1074\/jbc.M401939200 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFsrep21837_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1590\/S0100-879X2004000600004","volume":"37","author":"VP Creydt","year":"2004","unstructured":"Creydt, V. P. et al. The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Braz. J. Med. Biol. Res. 37, 799\u2013808 (2004).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"BFsrep21837_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/toxins3060626","volume":"3","author":"S Schuller","year":"2011","unstructured":"Schuller, S. Shiga toxin interaction with human intestinal epithelium. Toxins (Basel) 3, 626\u2013639, 10.3390\/toxins3060626 (2011).","journal-title":"Toxins (Basel)"},{"key":"BFsrep21837_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1348-0421.1993.tb01681.x","volume":"37","author":"Y Takeda","year":"1993","unstructured":"Takeda, Y., Kurazono, H. & Yamasaki, S. Vero toxins (Shiga\u2010like toxins) produced by enterohemorrhagic Escherichia coli (verocytotoxin\u2010producing E. coli). Microbiol. Immunol. 37, 591\u2013599 (1993).","journal-title":"Microbiol. Immunol."},{"key":"BFsrep21837_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","volume":"53","author":"M Michael","year":"2009","unstructured":"Michael, M., Elliott, E. J., Craig, J. C., Ridley, G. & Hodson, E. M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 53, 259\u2013272 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"BFsrep21837_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/s0140-6736(05)71144-2","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr, P. I., Gordon, C. A. & Chandler, W. L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365, 1073\u20131086, 10.1016\/s0140-6736(05)71144-2 (2005).","journal-title":"Lancet"},{"key":"BFsrep21837_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/emmm.201100169","volume":"3","author":"D Orth\u2010H\u00f6ller","year":"2011","unstructured":"Orth\u2010H\u00f6ller, D., Riedl, M. & W\u00fcrzner, R. Inhibition of terminal complement activation in severe Shiga toxin\u2010associated HUS\u2013perfect example for a fast track from bench to bedside. EMBO Mol. Med. 3, 617\u2013619 (2011).","journal-title":"EMBO Mol. Med."},{"key":"BFsrep21837_CR14","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1016\/j.vaccine.2006.02.035","volume":"24","author":"MJ Smith","year":"2006","unstructured":"Smith, M. J., Teel, L. D., Carvalho, H. M., Melton-Celsa, A. R. & O\u2019Brien, A. D. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24, 4122\u20134129 (2006).","journal-title":"Vaccine"},{"key":"BFsrep21837_CR15","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1073\/pnas.0510843103","volume":"103","author":"SX Wen","year":"2006","unstructured":"Wen, S. X., Teel, L. D., Judge, N. A. & O\u2019Brien, A. D. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl. Acad. Sci. USA 103, 7082\u20137087 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep21837_CR16","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.vaccine.2009.01.115","volume":"27","author":"X Gao","year":"2009","unstructured":"Gao, X. et al. Immunogenicity of a novel Stx2B\u2013Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157: H7 infection. Vaccine 27, 2070\u20132076 (2009).","journal-title":"Vaccine"},{"key":"BFsrep21837_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1086\/323082","volume":"184","author":"S Yamagami","year":"2001","unstructured":"Yamagami, S. et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184, 738\u2013742 (2001).","journal-title":"J. Infect. Dis."},{"key":"BFsrep21837_CR18","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1128\/IAI.01247-06","volume":"74","author":"MJ Smith","year":"2006","unstructured":"Smith, M. J., Carvalho, H. M., Melton-Celsa, A. R. & O\u2019Brien, A. D. The 13C4 monoclonal antibody that neutralizes Shiga toxin type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect. Immun. 74, 6992\u20136998 (2006).","journal-title":"Infect. Immun."},{"key":"BFsrep21837_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1139\/W10-087","volume":"56","author":"Q Wang","year":"2010","unstructured":"Wang, Q. et al. Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models. Can. J. Microbiol. 56, 1003\u20131010 (2010).","journal-title":"Can. J. Microbiol."},{"key":"BFsrep21837_CR20","doi-asserted-by":"publisher","first-page":"7669","DOI":"10.1073\/pnas.112058999","volume":"99","author":"K Nishikawa","year":"2002","unstructured":"Nishikawa, K. et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA 99, 7669\u20137674, 10.1073\/pnas.112058999 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep21837_CR21","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1086\/430388","volume":"191","author":"K Nishikawa","year":"2005","unstructured":"Nishikawa, K. et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J. Infect. Dis. 191, 2097\u20132105, 10.1086\/430388 (2005).","journal-title":"J. Infect. Dis."},{"key":"BFsrep21837_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1086\/381124","volume":"189","author":"M Watanabe","year":"2004","unstructured":"Watanabe, M. et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J. Infect. Dis. 189, 360\u2013368, 10.1086\/381124 (2004).","journal-title":"J. Infect. Dis."},{"key":"BFsrep21837_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bmc.2005.07.052","volume":"14","author":"Y Yamada","year":"2006","unstructured":"Yamada, Y., Miura, Y., Sakaki, A., Yoshida, T. & Kobayashi, K. Design of multifunctional peptides expressing both antimicrobial activity and shiga toxin neutralization activity. Bioorg. Med. Chem. 14, 77\u201382, 10.1016\/j.bmc.2005.07.052 (2006).","journal-title":"Bioorg. Med. Chem."},{"key":"BFsrep21837_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbagen.2006.03.018","volume":"1760","author":"Y Miura","year":"2006","unstructured":"Miura, Y., Sakaki, A., Kamihira, M., Iijima, S. & Kobayashi, K. A globotriaosylceramide (Gb3Cer) mimic peptide isolated from phage display library expressed strong neutralization to Shiga toxins. Biochim. Biophys. Acta. 1760, 883\u2013889, 10.1016\/j.bbagen.2006.03.018 (2006).","journal-title":"Biochim. Biophys. Acta."},{"key":"BFsrep21837_CR25","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1096\/fj.06-6572fje","volume":"20","author":"K Nishikawa","year":"2006","unstructured":"Nishikawa, K. et al. A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J. 20, 2597\u20132599, 10.1096\/fj.06-6572fje (2006).","journal-title":"FASEB J."},{"key":"BFsrep21837_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1128\/IAI.01022-09","volume":"78","author":"M Watanabe-Takahashi","year":"2010","unstructured":"Watanabe-Takahashi, M. et al. An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect. Immun. 78, 177\u2013183, 10.1128\/IAI.01022-09 (2010).","journal-title":"Infect. Immun."},{"key":"BFsrep21837_CR27","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1128\/IAI.01256-12","volume":"81","author":"K Tsutsuki","year":"2013","unstructured":"Tsutsuki, K., Watanabe-Takahashi, M., Takenaka, Y., Kita, E. & Nishikawa, K. Identification of a peptide-based neutralizer that potently inhibits both Shiga toxins 1 and 2 by targeting specific receptor-binding regions. Infect. Immun. 81, 2133\u20132138 (2013).","journal-title":"Infect. Immun."},{"key":"BFsrep21837_CR28","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jam.12451","volume":"116","author":"R Bernedo\u2010Navarro","year":"2014","unstructured":"Bernedo\u2010Navarro, R. et al. Peptides derived from phage display libraries as potential neutralizers of Shiga toxin\u2010induced cytotoxicity in vitro and in vivo . J. Appl. Microbiol. 116, 1322\u20131333 (2014).","journal-title":"J. Appl. Microbiol."},{"key":"BFsrep21837_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pep.2009.05.005","volume":"67","author":"W Tu","year":"2009","unstructured":"Tu, W. et al. Improved production of holotoxin Stx2 with biological activities by using a single-promoter vector and an auto-induction expression system. Protein Expr. Purif. 67, 169\u2013174 (2009).","journal-title":"Protein Expr. Purif."},{"key":"BFsrep21837_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ilar.38.1.41","volume":"38","author":"JD Clark","year":"1997","unstructured":"Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E. & Kohn, D. F. The 1996 guide for the care and use of laboratory animals. ILAR J. 38, 41\u201348 (1997).","journal-title":"ILAR J."},{"key":"BFsrep21837_CR31","doi-asserted-by":"publisher","first-page":"W288","DOI":"10.1093\/nar\/gks419","volume":"40","author":"P Th\u00e9venet","year":"2012","unstructured":"Th\u00e9venet, P. et al. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 40, W288\u2013W293 (2012).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep21837_CR32","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/bioinformatics\/btu097","volume":"30","author":"BG Pierce","year":"2014","unstructured":"Pierce, B. G. et al. ZDOCK server: interactive docking prediction of protein\u2013protein complexes and symmetric multimers. Bioinformatics 30, 1771\u20131773 (2014).","journal-title":"Bioinformatics"},{"key":"BFsrep21837_CR33","doi-asserted-by":"publisher","first-page":"W249","DOI":"10.1093\/nar\/gkr431","volume":"39","author":"N London","year":"2011","unstructured":"London, N., Raveh, B., Cohen, E., Fathi, G. & Schueler-Furman, O. Rosetta FlexPepDock web server\u2014high resolution modeling of peptide\u2013protein interactions. Nucleic Acids Res. 39, W249\u2013W253 (2011).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep21837_CR34","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00204-010-0639-0","volume":"85","author":"Y-N Liu","year":"2011","unstructured":"Liu, Y.-N. et al. Shiga toxin type 2 (Stx2), a potential agent of bioterrorism, has a short distribution and a long elimination half-life, and induces kidney and thymus lesions in rats. Arch. Toxicol. 85, 1133\u20131140 (2011).","journal-title":"Arch. Toxicol."},{"key":"BFsrep21837_CR35","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1074\/jbc.M107472200","volume":"277","author":"AM Soltyk","year":"2002","unstructured":"Soltyk, A. M. et al. A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. J. Biol. Chem. 277, 5351\u20135359 (2002).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep21837.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep21837","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep21837.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T22:35:35Z","timestamp":1672871735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep21837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,2,26]]}},"alternative-id":["BFsrep21837"],"URL":"https:\/\/doi.org\/10.1038\/srep21837","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]},"assertion":[{"value":"27 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21837"}}